与印度北部一家教学医院常规使用的其他氨基糖苷类药物相比,伊塞帕米星对革兰氏阴性菌的体外活性。

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Journal of Laboratory Physicians Pub Date : 2023-03-22 eCollection Date: 2023-09-01 DOI:10.1055/s-0043-1761928
Tasneem Siddiqui, Mitra Kar, Akanksha Dubey, Sangram Singh Patel, Chinmoy Sahu
{"title":"与印度北部一家教学医院常规使用的其他氨基糖苷类药物相比,伊塞帕米星对革兰氏阴性菌的体外活性。","authors":"Tasneem Siddiqui, Mitra Kar, Akanksha Dubey, Sangram Singh Patel, Chinmoy Sahu","doi":"10.1055/s-0043-1761928","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>  Isepamicin is a 1-N-S-a-hydroxy-b-aminopropionyl derivative of gentamicin B and the spectrum of pathogenic microorganisms covered by it and its effectiveness is similar to that of amikacin except the action of aminoglycoside inhibitor enzymes is ineffectual on it. <b>Material and Methods</b>  We performed a prospective study in the Bacteriology section of the Department of Microbiology at a 1,600-bedded hospital in Northern India from Jan 2022 to March 2022. Isepamicin was tested for susceptibility against gram-negative bacteria, identified by routine biochemicals and matrix-assisted-desorption/ionization -time of flight-mass spectrometry (MALDI-TOF-MS) assay. The antibiotic susceptibility testing for each of the isolates was performed by Kirby Bauer's disc diffusion method, according to the CLSI 2019 guidelines. <b>Results</b>  The majority of isolates were obtained from blood samples (50, 39.1%). Among the non-inducible <i>Enterobacteriaceae</i> , <i>Escherichia coli</i> was least susceptible to amikacin (8/27, 29.63%) and most susceptible to isepamicin (18/27, 66.67%). <i>Klebsiella pneumoniae</i> followed the same pattern of susceptibility as <i>E. coli</i> and was least susceptible to Amikacin (20/46, 43.48%) and most susceptible to isepamicin (24/46, 52.17%). <i>Enterobacter cloacae</i> (6/7, 85.71%) was most susceptible to both amikacin and isepamicin, followed by 71.43% (5/7, 71.43%) susceptibility to gentamicin and tobramycin each. <i>Enterobacter aerogenes</i> was equally 53.33% (8/15) susceptible to all antibiotics. <i>Pseudomonas aeruginosa</i> was the most susceptible isolate to all antibiotics (18/21, 85.71%). <b>Conclusion</b>  Isepamicin is a potential antimicrobial agent for treating an array of gram-negative bacteria-associated infections and shows better in vitro activity than older aminoglycoside agents.</p>","PeriodicalId":16149,"journal":{"name":"Journal of Laboratory Physicians","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/2c/10-1055-s-0043-1761928.PMC10411113.pdf","citationCount":"0","resultStr":"{\"title\":\"In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India.\",\"authors\":\"Tasneem Siddiqui, Mitra Kar, Akanksha Dubey, Sangram Singh Patel, Chinmoy Sahu\",\"doi\":\"10.1055/s-0043-1761928\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background</b>  Isepamicin is a 1-N-S-a-hydroxy-b-aminopropionyl derivative of gentamicin B and the spectrum of pathogenic microorganisms covered by it and its effectiveness is similar to that of amikacin except the action of aminoglycoside inhibitor enzymes is ineffectual on it. <b>Material and Methods</b>  We performed a prospective study in the Bacteriology section of the Department of Microbiology at a 1,600-bedded hospital in Northern India from Jan 2022 to March 2022. Isepamicin was tested for susceptibility against gram-negative bacteria, identified by routine biochemicals and matrix-assisted-desorption/ionization -time of flight-mass spectrometry (MALDI-TOF-MS) assay. The antibiotic susceptibility testing for each of the isolates was performed by Kirby Bauer's disc diffusion method, according to the CLSI 2019 guidelines. <b>Results</b>  The majority of isolates were obtained from blood samples (50, 39.1%). Among the non-inducible <i>Enterobacteriaceae</i> , <i>Escherichia coli</i> was least susceptible to amikacin (8/27, 29.63%) and most susceptible to isepamicin (18/27, 66.67%). <i>Klebsiella pneumoniae</i> followed the same pattern of susceptibility as <i>E. coli</i> and was least susceptible to Amikacin (20/46, 43.48%) and most susceptible to isepamicin (24/46, 52.17%). <i>Enterobacter cloacae</i> (6/7, 85.71%) was most susceptible to both amikacin and isepamicin, followed by 71.43% (5/7, 71.43%) susceptibility to gentamicin and tobramycin each. <i>Enterobacter aerogenes</i> was equally 53.33% (8/15) susceptible to all antibiotics. <i>Pseudomonas aeruginosa</i> was the most susceptible isolate to all antibiotics (18/21, 85.71%). <b>Conclusion</b>  Isepamicin is a potential antimicrobial agent for treating an array of gram-negative bacteria-associated infections and shows better in vitro activity than older aminoglycoside agents.</p>\",\"PeriodicalId\":16149,\"journal\":{\"name\":\"Journal of Laboratory Physicians\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/2c/10-1055-s-0043-1761928.PMC10411113.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Laboratory Physicians\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0043-1761928\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laboratory Physicians","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1761928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景 伊塞帕米星是庆大霉素 B 的 1-N-S-a-羟基-b-氨基丙酰基衍生物,除了氨基糖苷类抑制酶对其无效外,其病原微生物谱和效力与阿米卡星相似。材料与方法 我们于 2022 年 1 月至 2022 年 3 月在印度北部一家拥有 1600 张病床的医院微生物科细菌室进行了一项前瞻性研究。通过常规生化指标和基质辅助解吸电离飞行时间质谱(MALDI-TOF-MS)检测,对革兰阴性细菌进行了伊塞帕米星药敏试验。根据 CLSI 2019 指南,采用柯比鲍尔氏盘扩散法对每种分离菌进行了抗生素药敏试验。结果 大多数分离物来自血液样本(50 个,占 39.1%)。在非诱导性肠杆菌科细菌中,大肠埃希菌对阿米卡星的敏感性最低(8/27,29.63%),而对异帕米星的敏感性最高(18/27,66.67%)。肺炎克雷伯菌对阿米卡星最不敏感(20/46,43.48%),而对异帕米星最敏感(24/46,52.17%)。泄殖腔肠杆菌(6/7,85.71%)对阿米卡星和异帕米星的敏感性最高,其次是庆大霉素和妥布霉素,敏感性分别为 71.43%(5/7,71.43%)。产气肠杆菌对所有抗生素的敏感率同样为 53.33%(8/15)。铜绿假单胞菌是对所有抗生素最敏感的分离株(18/21,85.71%)。结论 伊塞帕米星是治疗一系列革兰氏阴性菌相关感染的潜在抗菌剂,其体外活性优于较老的氨基糖苷类药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India.

In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India.

Background  Isepamicin is a 1-N-S-a-hydroxy-b-aminopropionyl derivative of gentamicin B and the spectrum of pathogenic microorganisms covered by it and its effectiveness is similar to that of amikacin except the action of aminoglycoside inhibitor enzymes is ineffectual on it. Material and Methods  We performed a prospective study in the Bacteriology section of the Department of Microbiology at a 1,600-bedded hospital in Northern India from Jan 2022 to March 2022. Isepamicin was tested for susceptibility against gram-negative bacteria, identified by routine biochemicals and matrix-assisted-desorption/ionization -time of flight-mass spectrometry (MALDI-TOF-MS) assay. The antibiotic susceptibility testing for each of the isolates was performed by Kirby Bauer's disc diffusion method, according to the CLSI 2019 guidelines. Results  The majority of isolates were obtained from blood samples (50, 39.1%). Among the non-inducible Enterobacteriaceae , Escherichia coli was least susceptible to amikacin (8/27, 29.63%) and most susceptible to isepamicin (18/27, 66.67%). Klebsiella pneumoniae followed the same pattern of susceptibility as E. coli and was least susceptible to Amikacin (20/46, 43.48%) and most susceptible to isepamicin (24/46, 52.17%). Enterobacter cloacae (6/7, 85.71%) was most susceptible to both amikacin and isepamicin, followed by 71.43% (5/7, 71.43%) susceptibility to gentamicin and tobramycin each. Enterobacter aerogenes was equally 53.33% (8/15) susceptible to all antibiotics. Pseudomonas aeruginosa was the most susceptible isolate to all antibiotics (18/21, 85.71%). Conclusion  Isepamicin is a potential antimicrobial agent for treating an array of gram-negative bacteria-associated infections and shows better in vitro activity than older aminoglycoside agents.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Laboratory Physicians
Journal of Laboratory Physicians MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
99
审稿时长
31 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信